SuperworthLumexa Imaging LMRI
Medical - Diagnostics & Research, Healthcare
$11.66
+7.07%
- Market cap
- $1.1B
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- not a meaningful number
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q1 FY25 | Q2 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|
| $245M | $251.4M | $252.5M | $264.2M | |
| SG&A | $17.5M | $18.7M | $20.3M | $24.4M |
| $25.5M | $27.7M | $19.4M | $23M | |
| Interest expense | $29.8M | $30.1M | $16.3M | $16.2M |
| Pre-tax income | −$4.3M | −$2.4M | $3.1M | $5.8M |
| $3.4M | $4.8M | $1.4M | $3M | |
| Net income | −$7.7M | −$7.2M | $1.7M | $2.7M |
| −$0.11 | −$0.10 | $0.02 | $0.03 | |
| 69.5M | 69.5M | 96M | 96M |
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Medical - Diagnostics & Research nearest Lumexa Imaging's size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| LMRILumexa Imaging | $1.1B | n/m | n/a | n/m | n/m | n/m | |
| NRCNRC Health | $485.1M | 87.7× | 35.1× | 3.5× | −0% | 4.2% | |
| CDNACareDx | $3.6B | 33.4× | 19.1× | 7.8× | +34% | 24.2% | |
| VCYTVeracyte | $3.9B | 34.2× | 66.8× | 6.9× | +17% | 20.4% | |
| BLLNBillionToOne | $5.1B | 166× | 151× | 12.8× | +90% | 9.5% | |
| LNTHLantheus | $6.5B | 24.2× | 24.0× | 4.2× | +2% | 17.7% | |
| CAICaris Life Sciences | $9B | 86.5× | 73.7× | 9.1× | +85% | 10.6% | |
| BIOBio-Rad Laboratories | $9.9B | 44.8× | 30.8× | 3.8× | +1% | 8.6% | |
| Peer median | $5.1B | 44.8× | 35.1× | 6.9× | +17% | 10.6% |
More on Lumexa Imaging
Each number over time
Its groups
About
- Industry
- Medical - Diagnostics & Research
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .